E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) |
|
E.1.1.1 | Medical condition in easily understood language |
Progressive loss of central vision, the distortion of images and straight lines, and the presence of blurry and dark areas in the central vision |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064930 |
E.1.2 | Term | Age-related macular degeneration |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10063947 |
E.1.2 | Term | Geographic atrophy |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of ISIS 696844 on the rate of change of the area of Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF) |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effect of ISIS 696844 on plasma FB levels and serum AH50 activity in AMD patients
To assess the effect of ISIS 696844 to slow reduction of low luminance visual acuity (LLVA)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal.
2. Vaccination against Neisseria meningitidis and Streptococcus pneumoniae received at least 2 weeks prior to first dose of investigational product
3. Well-demarcated geographic atrophy (GA) due to AMD
4. Best-corrected visual acuity (BCVA) letter score of 35 letters (approx. 20/200 Snellen equivalent) or better on the ETDRS chart
5. Must have clear ocular media and adequate pupillary dilation in the study eye to permit high-quality fundus imaging
|
|
E.4 | Principal exclusion criteria |
1.Clinically-significant abnormalities in medical history
2. A lack of full recovery from any infection for at least 14 days prior to the Study Drug administration
3. Chronic treatment with steroids, including topically or intravitreally administered
4. History or presence of diabetic retinopathy or diabetic macular edema (DME)
5. History or presence of a disease other than AMD that could affect vision or safety assessments
6. Prior treatment with another investigational drug, biological agent, or device
7. Other protocol-specified inclusion/exclusion criteria may apply
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the absolute change in the GA area at Week 49 compared to baseline, as measured by FAF in study eye. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary efficacy endpoints include:
• Percent change in levels of plasma FB from Baseline
• Percent change in levels of serum AH50 activity from Baseline
• Absolute change in LLVA score from Baseline at Week 49
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Please, refer to Appendix A in the protocol for a detailed schedule of procedures |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
New Zealand |
United States |
Austria |
Hungary |
Netherlands |
Poland |
Spain |
Czechia |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The End-of-Study is last patient, last Post-Treatment visit or last study-related procedure. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 5 |